- Home
- NTRB vs CTOR Comparison
NTRB vs CTOR Comparison
Compare NTRB & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- CTOR
- Stock Information
- Founded
- NTRB 2016
- CTOR 2021
- Country
- NTRB United States
- CTOR United States
- Employees
- NTRB N/A
- CTOR N/A
- Industry
- NTRB Industrial Specialties
- CTOR
- Sector
- NTRB Health Care
- CTOR
- Exchange
- NTRB Nasdaq
- CTOR NYSE
- Market Cap
- NTRB 77.9M
- CTOR 89.9M
- IPO Year
- NTRB N/A
- CTOR N/A
- Fundamental
- Price
- NTRB $4.37
- CTOR $1.06
- Analyst Decision
- NTRB
- CTOR Strong Buy
- Analyst Count
- NTRB 0
- CTOR 2
- Target Price
- NTRB N/A
- CTOR $4.50
- AVG Volume (30 Days)
- NTRB 27.6K
- CTOR 5.7M
- Earning Date
- NTRB 12-04-2024
- CTOR 12-24-2024
- Dividend Yield
- NTRB N/A
- CTOR N/A
- EPS Growth
- NTRB N/A
- CTOR N/A
- EPS
- NTRB N/A
- CTOR N/A
- Revenue
- NTRB $2,021,771.00
- CTOR N/A
- Revenue This Year
- NTRB N/A
- CTOR N/A
- Revenue Next Year
- NTRB N/A
- CTOR N/A
- P/E Ratio
- NTRB N/A
- CTOR N/A
- Revenue Growth
- NTRB N/A
- CTOR N/A
- 52 Week Low
- NTRB $2.22
- CTOR $0.85
- 52 Week High
- NTRB $9.60
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- NTRB 47.75
- CTOR N/A
- Support Level
- NTRB $3.87
- CTOR N/A
- Resistance Level
- NTRB $4.86
- CTOR N/A
- Average True Range (ATR)
- NTRB 0.48
- CTOR 0.00
- MACD
- NTRB 0.08
- CTOR 0.00
- Stochastic Oscillator
- NTRB 65.05
- CTOR 0.00
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.